Earnings History Data for Biohaven Ltd. (BHVN) - NYSE NASDAQ

To lookup another company type a stock symbol and press 'Go'. The overview will show the earnings release info that is available in TheStockCatalyst database for the company.

For historic stock the Extended Hours price data shown are from just before market open on the day of release for premarket earnings releases and of the day after release for afterhours earnings releases. The normal price data is from just before market close on the days of release for premarket releases and the day after release for afterhours releases.

See the full list of available companies here.

Biohaven Ltd.

Biohaven Pharmaceutical Holding Company Ltd. is a biopharmaceutical company. It focuses on the identification and development of orphan neurologic indications and other neurological pathways. The company's pipeline includes BHV-0223, which is a formulation of a glutamate-modulating agent; BHV-4157, which is a new chemical entity that modulates glutamate and BHV-5000, which is an in-licensed investigational agent of the Company targeting N-Methyl-D-Aspartate receptor antagonism which are in clinical trial stage. Biohaven Pharmaceutical Holding Company Ltd. is based in NEW HAVEN, United States.

Release Date	Time	Est. Time	Symbol	Name	Market Cap (M)	Rep. EPS	Est. EPS	Last years EPS	SeekingAlpha Headline	Price	Change	Ext. Hours Price	Ext. Hours Change	52 Week Range	Volume	Avg. Volume	Ext. Hours Volume
29-02-2024	AH		BHVN	Biohaven Ltd.	3,822	-1.81	-1.41	0.00	Biohaven GAAP EPS of -$1.81 misses by $0.40 [2/29/2024 6:02 PM]	49.63	1.49 (3.11%)	48.10	-0.04 (-0.08%)	12.35 - 51.78	1,317,261	910,000	85,010
Biohaven GAAP EPS of -$1.81 misses by $0.40 [2/29/2024 6:02 PM]
14-11-2023	AH		BHVN	Biohaven Ltd.	1,954	-1.50	-1.33	0.00	Biohaven Non-GAAP EPS of -$1.44 [11/14/2023 5:13 PM]	29.16	-0.62 (-2.08%)	29.78	0.0 (0.00%)	12.35 - 31.21	664,867	1,170,000	198,591
Biohaven Non-GAAP EPS of -$1.44 [11/14/2023 5:13 PM]
31-07-2023	PM		BHVN	Biohaven Ltd.	1,257	-1.32	-1.24	0.00	Biohaven Non-GAAP EPS of -$1.25 misses by $0.02 [7/31/2023 12:09 PM]	19.69	0.64 (3.36%)	0.0	0.0 (0.00%)	5.54 - 26.64	1,218,001	1,540,000	0
Biohaven Non-GAAP EPS of -$1.25 misses by $0.02 [7/31/2023 12:09 PM]
12-05-2023	AH		BHVN	Biohaven Ltd.	977.00	-1.03	-1.39	0.00	Biohaven Non-GAAP EPS of -$0.98 [5/12/2023 5:19 PM]	14.49	0.88 (6.47%)	13.71	0.10 (0.73%)	5.54 - 20.57	655,416	590,000	8,144

23-03-2023	AH		BHVN	Biohaven Ltd.	937.00	-3.32	-1.24	0.00	Biohaven Non-GAAP EPS of -$1.27 beats by $0.01 [3/23/2023 4:39 PM]	14.21	0.80 (6.01%)	13.48	0.08 (0.60%)	5.54 - 20.57	999,217	1,070,000	212
Biohaven Non-GAAP EPS of -$1.27 beats by $0.01 [3/23/2023 4:39 PM]
09-11-2022	PM		BHVN	Biohaven Ltd.	952.12	-1.75	-2.53	-2.63	Biohaven Non-GAAP EPS of -$1.25 [11/9/2022 8:51 AM]	14.68	-0.89 (-5.72%)	15.00	-0.57 (-3.65%)	5.54 - 17.39	585,200	900,000	308
Biohaven Non-GAAP EPS of -$1.25 [11/9/2022 8:51 AM] Biohaven Ltd. Reports Third Quarter 2022 Financial Results and Reports Recent Business Developments [Nov-09-22 07:00AM] George Soros Stock Portfolio: Top 10 Stock Picks [Nov-08-22 11:52AM]
05-08-2022	PM		BHVN	Biohaven Pharmaceutical	10,309	-6.21	-2.79	0.00	Biohaven Pharmaceuticals Non-GAAP EPS of -$3.82 misses by $1.57, revenue of $194M misses by $16.6M [8/5/2022 7:24 AM]	146.98	-0.12 (-0.08%)	146.98	0.0 (0.00%)	79.01 - 151.51	309,512	590,000	978
Biohaven Pharmaceuticals Non-GAAP EPS of -$3.82 misses by $1.57, revenue of $194M misses by $16.6M [8/5/2022 7:24 AM] Biohaven Reports Second Quarter 2022 Financial Results and Reports Recent Business Developments [Aug-05-22 07:00AM] Intellia Therapeutics, Inc. (NTLA) Reports Q2 Loss, Tops Revenue Estimates [Aug-04-22 08:45AM] Biohaven Pharmaceutical Holding Company Ltd. (BHVN) Reports Q2 Loss, Tops Revenue Estimates [Aug-05-22 08:15AM]
10-05-2022	PM	7:00 AM ET (May 11)	BHVN	Biohaven Pharmaceutical Holding Company Ltd.	6,840	-2.97	-2.52	-4.21	Biohaven Pharmaceuticals Non-GAAP EPS of -$1.62 beats by $0.65, revenue of $318.85M beats by $135.14M [5/10/2022 7:01 AM]	141.00	57.86 (69.59%)	141.40	58.26 (70.07%)	65.24 - 151.51	15,907,814	677,623	1,479,452
Biohaven Pharmaceuticals Non-GAAP EPS of -$1.62 beats by $0.65, revenue of $318.85M beats by $135.14M [5/10/2022 7:01 AM] Pfizer to acquire Biohaven in ~$11.6B deal; Biohaven stock soars 72% [5/10/2022 7:22 AM] Is a Surprise Coming for Biohaven Pharmaceutical (BHVN) This Earnings Season? [May-06-22 09:18AM] Biohaven to Discuss First Quarter 2022 Financial Results and Recent Business Developments on May 11, 2022 [May-09-22 07:30AM] Biohaven Reports First Quarter 2022 Financial Results and Reports Recent Business Developments [May-10-22 06:50AM] Pfizer to Acquire Biohaven Pharmaceuticals [May-10-22 06:45AM] UPDATE 1-Pfizer to buy Biohaven Pharmaceutical in $11.6 bln deal [May-10-22 07:00AM] Pfizer to buy Biohaven Pharmaceutical in $11.6 billion deal [May-10-22 06:56AM] Pfizer to acquire Biohaven Pharma for $11.6 billion in cash sending Biohaven shares up 74% premarket [May-10-22 06:56AM] Pfizer to Acquire Biohaven Pharmaceutical for $11.6 Billion [May-10-22 07:12AM] Pfizer to Buy Biohaven Pharmaceuticals for $11.6 Billion [May-10-22 07:12AM] Pfizer to buy migraine drugmaker Biohaven in $11.6-billion deal [May-10-22 06:56AM] Pfizer Buys Biohaven In A $12 Billion Deal That 'Couldn't Have Come At A Better Time' [May-10-22 09:08AM] Biohaven Pharmaceutical Holding Company Ltd. (BHVN) Reports Q1 Loss, Tops Revenue Estimates [May-10-22 08:05AM] Cash-rich Pfizer to pay $11.6 billion for Biohaven in biggest deal since 2016 [May-10-22 06:56AM] Pfizer acquires Biohaven for $11.6 billion in cash [May-10-22 09:51AM] Stock Market Bounces As Nasdaq Rallies 2.1%; This Stock Soars 71%, But Another One Plunges 53% [May-10-22 10:31AM] Stock Market Bounce Fades As S&P 500 Trims Gain To Just 0.3% [May-10-22 11:03AM] Stock Market Fades, Mixed At Midday; A Defensive Group Sells Off [May-10-22 12:04PM] Pfizer to pay $11.6 billion for Biohaven to tap migraine market [May-10-22 06:56AM] Pfizer Is Spending $11.6 Billion on Biohaven. Its Plans Point to a Lot More M&A. [May-10-22 02:26PM] Nasdaq Leads Upside As Indexes Turn Positive; This Dow Jones Stock Nears Buy Point [May-10-22 03:10PM] 10 Stocks Making Headlines Today [May-10-22 03:41PM]
25-02-2022	PM	7:45 AM ET (Feb 25)	BHVN	Biohaven Pharmaceutical Holding Company Ltd.	8,780	-3.01	-2.07	-3.62	Biohaven Pharmaceuticals Non-GAAP EPS of -$2.32 misses by $0.39, revenue of $190.01M beats by $14.47M [2/25/2022 7:49 AM]	121.98	-11.83 (-8.84%)	136.00	2.19 (1.64%)	62.57 - 151.51	780,432	440,000	4,024
Biohaven Pharmaceuticals Q4 2021 Earnings Preview [2/24/2022 12:37 PM] Biohaven in licensing pact with Bristol Myers; to acquire Channel Biosciences [2/25/2022 7:39 AM] Biohaven Pharmaceuticals Non-GAAP EPS of -$2.32 misses by $0.39, revenue of $190.01M beats by $14.47M [2/25/2022 7:49 AM] Pfizer, Biohaven's rimegepant gets EMA panel nod for migraine treatment [2/25/2022 8:40 AM] Sangamo Therapeutics (SGMO) Reports Q4 Loss, Lags Revenue Estimates [Feb-24-22 06:20PM] BIOHAVEN REPORTS FOURTH QUARTER AND FULL YEAR 2021 FINANCIAL RESULTS AND RECENT BUSINESS DEVELOPMENTS [Feb-25-22 07:00AM] Biohaven and Pfizer Receive Positive CHMP Opinion for Migraine Treatment [Feb-25-22 06:59AM] Biohaven Acquires Kv7 Ion Channel Platform for the Treatment of Epilepsy and Other Neurologic Disorders From Channel Biosciences, a Subsidiary of Knopp Biosciences [Feb-25-22 06:55AM] Biohaven Licenses Taldefgrobep Alfa, a Phase 3-Ready Anti-Myostatin Adnectin for Spinal Muscular Atrophy (SMA), from Bristol Myers Squibb [Feb-25-22 06:50AM] Biohaven Pharmaceutical Holding Company Ltd. (BHVN) Reports Q4 Loss, Tops Revenue Estimates [Feb-25-22 08:25AM] Biohaven Further Deepens Its Neurology Pipeline With Bristol Myers, Knopp Biosciences Deals [Feb-25-22 08:43AM] Biohaven Stock Dives As 'Hand-Wringing' Clouds Two Potentially Promising Deals [Feb-25-22 02:19PM]
09-11-2021	PM	7:00 AM ET (Nov 9)	BHVN	Biohaven Pharmaceutical Holding Company Ltd.	9,680	-2.63	-2.44	-3.27	Biohaven Pharmaceuticals EPS beats by $0.11, beats on revenue [11/9/2021 8:33 AM]	121.58	-18.18 (-13.01%)	118.00	-21.77 (-15.58%)	62.57 - 151.51	2,538,376	260,000	105,911
Biohaven Pharmaceuticals Q3 2021 Earnings Preview [11/8/2021 11:47 AM] Biohaven Pharmaceuticals EPS beats by $0.11, beats on revenue [11/9/2021 8:33 AM] Pfizer to gain ex-U.S. rights to Biohaven migraine med Nurtec in up to $1.24B deal [11/9/2021 8:13 AM] Biohaven falls 15% on apparent disappointment that Pfizer deal isn't a buyout [11/9/2021 9:06 AM] Biohaven and Pfizer Enter Strategic Collaboration for the Commercialization of Rimegepant Outside the United States [Nov-09-21 07:46AM] Biohaven Reports Third Quarter 2021 Financial Results And Recent Business Developments [Nov-09-21 07:45AM] Biohaven's stock slides 15% on deal with Pfizer for its migraine drug [Nov-09-21 08:07AM] Biohaven, Pfizer enter up to $1.24 billion deal to market migraine drugs [Nov-09-21 08:06AM] UPDATE 1-Biohaven, Pfizer enter up to $1.24 bln deal to market migraine drugs [Nov-09-21 08:31AM] Why Biohaven Pharmaceuticals Stock Crumbled On This Premium Deal With Pfizer [Nov-09-21 09:48AM] Biohaven Pharmaceutical Holding Company Ltd. (BHVN) Reports Q3 Loss, Tops Revenue Estimates [Nov-09-21 08:55AM] Pfizer Gains Outside US Rights To Biohaven's Migraine Treatment For $500M [Nov-09-21 10:49AM] UPDATE 2-Pfizer to market Biohaven's migraine drugs overseas [Nov-09-21 08:31AM]
09-08-2021	PM	7:30 AM ET (Aug 9)	BHVN	Biohaven Pharmaceutical Holding Company Ltd.	8,240	-3.23	-2.77	-2.55	Biohaven Pharmaceuticals EPS misses by $0.38, beats on revenue [8/9/2021 9:45 AM]	118.00	-6.54 (-5.25%)	125.50	0.96 (0.77%)	57.66 - 132.91	626,289	540,000	6,935
Biohaven Pharmaceuticals EPS misses by $0.38, beats on revenue [8/9/2021 9:45 AM] Biohaven Reports Second Quarter 2021 Financial Results And Recent Business Developments [Aug-09-21 07:00AM] Biohaven Pharmaceutical Holding Company Ltd. (BHVN) Reports Q2 Loss, Tops Revenue Estimates [Aug-09-21 08:45AM] Biohaven (BHVN) Q2 Earnings Miss, Nurtec Uptake Still Strong [Aug-09-21 12:13PM]
10-05-2021	PM	7:30 AM ET (May 10)	BHVN	Biohaven Pharmaceutical Holding Company Ltd.	4,570	-4.21	-2.99	-2.39	Biohaven Pharmaceuticals EPS misses by $0.37, beats on revenue [5/10/2021 7:52 AM]	69.32	-2.12 (-2.97%)	69.90	-1.54 (-2.16%)	42.74 - 100.77	710,327	410,000	1,234
Biohaven Pharmaceuticals EPS misses by $0.37, beats on revenue [5/10/2021 7:52 AM] Biohaven Pharmaceutical Holding Co. Ltd. to Host Earnings Call [May-10-21 06:45AM] Biohaven Reports First Quarter 2021 Financial Results and Recent Business Developments [May-10-21 07:30AM] Biohaven Pharmaceutical Holding Company Ltd. (BHVN) Reports Q1 Loss, Tops Revenue Estimates [May-10-21 08:50AM] /C O R R E C T I O N -- Biohaven Pharmaceutical Holding Company Ltd./ [May-10-21 04:08PM]
01-03-2021	PM	8:00 AM ET (Mar 1)	BHVN	Biohaven Pharmaceutical Holding Company Ltd.	5,000	-3.62	-2.89	-2.85	Biohaven Pharmaceuticals EPS misses by $0.13, beats on revenue [3/1/2021 8:32 AM]	86.50	1.52 (1.79%)	85.30	0.32 (0.38%)	26.56 - 100.77	370,262	502,575	260
Biohaven Pharmaceuticals EPS misses by $0.13, beats on revenue [3/1/2021 8:32 AM] Recap: Biohaven Pharmaceutical Q4 Earnings [Mar-01-21 07:59AM] Biohaven Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Business Developments [Mar-01-21 07:30AM] Biohaven Pharmaceutical Holding Co. Ltd. to Host Earnings Call [Mar-01-21 06:30AM]
09-11-2020	PM	7:45 AM ET (Nov 9)	BHVN	Biohaven Pharmaceutical Holding Company Ltd.	5,240	-3.27	-2.74	-2.04	Biohaven Pharmaceuticals EPS beats by $0.19, misses on revenue [11/9/2020 8:03 AM]	81.38	-1.02 (-3.48%)	84.25	-0.06 (-0.07%)	26.56 - 89.46	1,072,719	565,257	221

10-08-2020	PM	Before the open (Aug 10)	BHVN	Biohaven Pharmaceutical Holding Company Ltd.	3,710	-2.55	-2.78	-2.35	Biohaven Pharmaceuticals EPS beats by $0.29, beats on revenue [8/10/2020 7:47 AM]	63.33	2.35 (-6.39%)	70.00	2.35 (3.47%)	26.56 - 78.75	532,876	580,031	704